Binds Receptor Patents (Class 424/143.1)
-
Patent number: 8952134Abstract: The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and C?3 and C?4 regions of a C? constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a C? constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.Type: GrantFiled: September 26, 2012Date of Patent: February 10, 2015Assignee: JN Biosciences LLCInventors: J. Yun Tso, Naoya Tsurushita
-
Patent number: 8945547Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: March 14, 2013Date of Patent: February 3, 2015Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
-
Patent number: 8946387Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, more particularly the extracellular domain of Fc?RIIB with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA, and block the Fc binding site of Fc?RIIB. The present invention also encompasses the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies.Type: GrantFiled: August 5, 2008Date of Patent: February 3, 2015Assignee: MacroGenics, Inc.Inventors: Scott Koenig, Maria Concetta Veri, Nadine Tuaillon, Ezio Bonvini
-
Patent number: 8945559Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.Type: GrantFiled: October 5, 2011Date of Patent: February 3, 2015Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Daniel B. Dix, Xiaolin Tang
-
Patent number: 8945558Abstract: The present inventors investigated the effects of anti-IL-6 receptor antibodies on improving the condition of infarcted areas in myocardial infarction, and on suppressing left ventricular remodeling after myocardial infarction. As a result, the administration of anti-IL-6 receptor antibodies significantly suppressed the increase of MPO activity in the infarcted area and suppressed myocardial MCP-1 expression in both the infarcted area and the non-infarcted area. Furthermore, echocardiography and histological examinations revealed that cardiac hypertrophy is also suppressed.Type: GrantFiled: October 20, 2006Date of Patent: February 3, 2015Assignee: Chugai Seiyaku Kabushiki KaishaInventor: Miyuki Kobara
-
Patent number: 8945565Abstract: Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.Type: GrantFiled: December 21, 2010Date of Patent: February 3, 2015Assignees: Selexys Pharmaceuticals Corporation, Oklahoma Medical Research FoundationInventors: Scott Rollins, Richard Alvarez, Russell Rother, Rodger P. McEver, Ziad S. Kawar
-
Patent number: 8945573Abstract: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.Type: GrantFiled: March 10, 2008Date of Patent: February 3, 2015Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Sathibalan Ponniah, George E. Peoples, Catherine E. Storrer, Michael Flora
-
Patent number: 8945548Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: GrantFiled: October 3, 2013Date of Patent: February 3, 2015Assignee: Novartis AGInventors: Jose M. Carballido Herrera, Stefan Hartle, Christoph Heusser, Ingo Klagge, Andrea Polzer, Christoph Schwaerzler, Gabriela Wochnik-Veltrup
-
Patent number: 8945564Abstract: Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody-containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.Type: GrantFiled: April 17, 2007Date of Patent: February 3, 2015Assignees: Novartis AG, Xoma Technology Ltd.Inventors: Xiaofeng Lu, Bao-Lu Chen, Kidisti Araya, Augustus Okhamafe
-
Patent number: 8945560Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.Type: GrantFiled: August 12, 2014Date of Patent: February 3, 2015Assignee: Kymab LimitedInventor: Jasper Rupert Clube
-
Patent number: 8940298Abstract: The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.Type: GrantFiled: September 4, 2008Date of Patent: January 27, 2015Assignee: The Regents of the University of CaliforniaInventors: Anna M. Wu, Robert E. Reiter, Eric J. Lepin, James D. Marks, Yu Zhou
-
Patent number: 8940302Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.Type: GrantFiled: October 9, 2012Date of Patent: January 27, 2015Assignees: Genentech, Inc., Hoffmann-La Roche Inc.Inventors: Lukas C. Amler, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
-
Publication number: 20150023965Abstract: Methods and compositions for treating a urothelial and/or a micropapillary carcinoma, such as a micropapillary urothelial carcinoma are disclosed.Type: ApplicationFiled: July 16, 2014Publication date: January 22, 2015Applicant: FOUNDATION MEDICINE, INC.Inventors: Siraj Mahamed Ali, Matthew J. Hawryluk, Jeffrey S. Ross, Philip James Stephens
-
Publication number: 20150017179Abstract: One embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount at least one anti-CD74 antibody; and at least one pharmaceutically acceptable carrier. Another embodiment of the present invention relates to a pharmaceutical composition, which includes a therapeutically effective amount of at least one anti-TNFR antibody; a therapeutically effective amount of at least one anti-MIF antibody; and at least one pharmaceutically acceptable carrier. Other embodiments of the present invention relate to methods of treating or preventing cardiac dysfunction, cardiodepression, burn injury-associated cardiac dysfunction, improving cardiac function in a subject following acute myocardial infarction, and identifying an MIF inhibitor.Type: ApplicationFiled: May 19, 2014Publication date: January 15, 2015Inventors: Brett P. GIROIR, Monte S. WILLIS, Vidal F. DE LA CRUZ, JR., Thais M. SIELECKI-DZURDZ
-
Publication number: 20150017178Abstract: The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts.Type: ApplicationFiled: February 19, 2014Publication date: January 15, 2015Inventor: Antonio Francesco DI NARO
-
Publication number: 20150010554Abstract: A pharmaceutical composition for the treatment of interleukin-6 (IL-6) related diseases, comprising an interleukin-6 antagonist (IL-6 antagonist) and immunosuppressants. The IL-6 antagonist is preferably an antibody to an interleukin-6 receptor (IL-6R).Type: ApplicationFiled: September 24, 2014Publication date: January 8, 2015Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Osamu OKUDA, Noriaki YOSHIDA, Ravinder Nath MAINI
-
Publication number: 20150010496Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.Type: ApplicationFiled: November 30, 2012Publication date: January 8, 2015Inventors: Vincenzo Cerundolo, Gurdyal S. Besra, Liam Cox
-
Patent number: 8926977Abstract: An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.Type: GrantFiled: October 27, 2010Date of Patent: January 6, 2015Assignee: UCB Pharma S.A.Inventors: Karen Margrete Miller, Marc Roger De Ryck, Christian Gilbert J. Wolff, Alastair David Griffiths Lawson, Helene Margaret Finney, Terence Seward Baker
-
Patent number: 8926976Abstract: Antibodies that modulate insulin receptor signaling are provided.Type: GrantFiled: September 24, 2010Date of Patent: January 6, 2015Assignee: Xoma Technology Ltd.Inventors: John Corbin, Mark Leslie White, Susan R. Watson, Vinay Bhaskar
-
Patent number: 8926979Abstract: Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan®), are also provided.Type: GrantFiled: November 1, 2006Date of Patent: January 6, 2015Assignees: Novartis AG, XOMA Technology Ltd.Inventors: Sharon Lea Aukerman, Mohammad Luqman
-
Patent number: 8926969Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.Type: GrantFiled: December 19, 2012Date of Patent: January 6, 2015Assignee: Takeda Pharmaceutical Company LimitedInventors: Kathleen Ann Elias, Gregory Landes, Shewta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
-
Patent number: 8920803Abstract: A method for the treatment of a condition which is characterized by CD 123-expressing cells in a patient comprises administering to the patient (i) an antibody or antibody fragment which binds selectively to IL-3R?(CD 123), and (ii) an immunostimulating complex which comprises saponin, a sterol and a phospholipid.Type: GrantFiled: June 15, 2011Date of Patent: December 30, 2014Assignee: CSL LimitedInventors: Debra Pauline Drane, Eugene Maraskovsky, Jefferey Stephen Boyle
-
Patent number: 8916162Abstract: Methods and compositions pertaining to botulinum neurotoxin (BoNT) light chain epitopes are provided. In particular, the methods and compositions relate to the use of real and mimetic BoNT light chain epitopes for generating an immune response in a subject, and for immunization against BoNT toxicity. Methods and compositions for detecting, isolating, and purifying BoNT epitopes and anti-BoNT antibodies are also provided.Type: GrantFiled: February 18, 2011Date of Patent: December 23, 2014Inventor: Alexey Gennadievich Zdanovsky
-
Patent number: 8916155Abstract: The present invention relates generally to binding agents useful in the selective depletion of T cells in vivo. More specifically, the invention relates to ICOS-binding agents which once bound to ICOS expressed on the surface of cells, in particular ICOS-bearing activated T cells, result in the in vivo depletion of cells to which they are bound. Methods of treating T cell related diseases using said ICOS-binding agents, and pharmaceutical compositions comprising said ICOS-binding agents, a method of identifying an ICOS-binding agent, and monoclonal anti-ICOS antibodies capable of eliminating cells in vivo which express ICOS on their surface are also provided.Type: GrantFiled: October 22, 2012Date of Patent: December 23, 2014Assignee: Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen PräsidentenInventor: Richard Kroczek
-
Publication number: 20140370004Abstract: In an aspect, a method of augmenting an immune response in a subject in need thereof, comprising identifying the subject, and treating the subject to inhibit the immune suppressive effect of CD71+ cells is provided. Further provided is a method of preventing, treating or ameliorating an infection in a subject, comprising administering to the subject an agent that reduces the level of CD71+ cells in the subject.Type: ApplicationFiled: June 13, 2014Publication date: December 18, 2014Inventor: Sing Sing Way
-
Patent number: 8911739Abstract: A method is provided for preventing rejection by an immune system of a recipient subject of a tissue transplanted from a donor subject into the recipient subject without the need for long-term administration of non-specific immunosuppressive drugs.Type: GrantFiled: February 9, 2010Date of Patent: December 16, 2014Assignees: Trustees of Columbia University in the City of New York, The National Institutes of Health (NIH)Inventors: Hong Jiang, Leonard Chess
-
Patent number: 8911726Abstract: A highly stable mutant of human IgG4 antibody is provided. Such antibody is an antibody in which the CH3 domain of human IgG4 is substituted with the CH3 domain of human IgG1 and which exhibits inhibited aggregate formation, an antibody in which the CH3 and CH2 domains of human IgG4 are substituted with the CH3 and CH2 domains of human IgG1, respectively, or an antibody in which arginine at position 409 indicated in the EU index proposed by Kabat et al. of human IgG4 is substituted with lysine and which exhibits inhibited aggregate formation.Type: GrantFiled: September 22, 2005Date of Patent: December 16, 2014Assignee: Kyowa Hakko Kirin Co., LtdInventors: Nobuaki Takahashi, Hideaki Yoshida
-
Patent number: 8911768Abstract: Methods for treating and preventing retinopathic conditions by administering an anti-VEGF compound to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.Type: GrantFiled: June 17, 2014Date of Patent: December 16, 2014Assignee: Allergan, Inc.Inventors: Scott M. Whitcup, David A. Weber
-
Publication number: 20140363442Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to CD47 of multiple mammalian species, block the binding of SIRPalpha and TSP1 to CD47, promote phagocytosis of susceptible cancer cells, and reverse TSP1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents for treating susceptible cancer cells, promoting their phagocytic uptake and clearance.Type: ApplicationFiled: June 11, 2014Publication date: December 11, 2014Inventors: William A. FRAZIER, Pamela T. MANNING, Gerhard FREY, Hwai Wen CHANG
-
Patent number: 8906632Abstract: The present invention relates to the use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma. More particularly, the present invention relates to a pharmaceutical composition for treating asthma comprising BLT2 inhibitors and a method for treating asthma using BLT2 inhibitors.Type: GrantFiled: December 9, 2011Date of Patent: December 9, 2014Assignee: Korea University Research & Business FoundationInventors: Jae-Hong Kim, Kyung-Jin Cho, Min-Hyuk Yoo
-
Patent number: 8901283Abstract: Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.Type: GrantFiled: May 22, 2012Date of Patent: December 2, 2014Assignee: Novo Nordisk A/SInventors: Petrus Johannes Louis Spee, Soeren Berg Padkaer
-
Patent number: 8900586Abstract: The present invention relates to an antibody binding to the domain 2 of human intercellular adhesion molecules-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and induce antigen-specific T cell tolerance, thereby be effective in the prevention and/or treatment of T cell-mediated immune disorders such as transplantation rejection, graft-versus-host disease, and autoimmune disease. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.Type: GrantFiled: July 5, 2011Date of Patent: December 2, 2014Assignees: Dinona Inc., SNU R&DB FoundationInventors: Seong Hoe Park, Kyeong Cheon Jung
-
Publication number: 20140348846Abstract: Provided herein are compositions comprising anti-HLA-Ib antibodies (monoclonal, mixed monoclonal, recombinant, chimeric, humanized or human antibodies) as IVIg mimetics and methods for using the same for the prevention, treatment, therapy and/or amelioration of inflammation induced diseases and allograft rejection. In certain embodiments, the anti-HLA-Ib antibodies strongly mimic IVIg in immunoreactivity to HLA class Ia (HLA-A, HLA-B and HLA-Cw) and Ib antigens (HLA-E, HLA-F and HLA-G). In certain embodiments, the anti-HLA-Ib antibodies strongly mimic IVIg in immunomodulatory or immunosuppressive activities. Methods are also provided herein to induce production of polyclonal anti-HLA-Ib antibodies in cancer patients for restoring anti-tumor activities of CD8+ T cells and NK cells, by active specific immunotherapy.Type: ApplicationFiled: January 10, 2013Publication date: November 27, 2014Inventors: Mepur H. Ravindranath, Paul I. Terasaki
-
Publication number: 20140348829Abstract: Provided are felinized antibodies and methods for treating or reducing the likelihood of developing a retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline. These methods require the administration of at least one felinized antibody or fragment thereof that specifically binds to CD11a and/or CD18, or ICAM-1, and/or decreases or prevents the binding of LFA-1 (CD11a/CD18 heterodimer) to ICAM-1. Also provided are veterinary compositions and methods of identifying candidate agents useful for treating or reducing retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline.Type: ApplicationFiled: April 8, 2014Publication date: November 27, 2014Applicant: CYTODYN INC.Inventor: Richard Trauger
-
Publication number: 20140348833Abstract: The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein said first antibody binds EGFR, said second antibody binds EGFR, said first and second antibody are non-cross-blocking, and the dosage regimen is such that CDC is obtained at the tumor site.Type: ApplicationFiled: March 6, 2014Publication date: November 27, 2014Applicant: GENMAB A/SInventors: Jan VAN DE WINKEL, Paul PARREN, Willem Karel BLEEKER, Klaus EDVARDSEN, Jeroen Lammerts VAN BUEREN, Thomas VALERIUS, Michael DECHANT, Wencke WEISNER, Sven BERGER
-
Patent number: 8895008Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: GrantFiled: May 10, 2013Date of Patent: November 25, 2014Assignee: Amgen Inc.Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Patent number: 8895000Abstract: The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.Type: GrantFiled: September 1, 2010Date of Patent: November 25, 2014Assignee: Morphotek, Inc.Inventors: Yuhong Zhou, Brian Tomkowicz, Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
-
Patent number: 8895010Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.Type: GrantFiled: October 12, 2012Date of Patent: November 25, 2014Assignees: Bristol-Myers Squibb Company, Domantis LimitedInventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
-
Patent number: 8895005Abstract: The present invention relates to agents which modulate the effect of a RAMP (Receptor Activity Modifying Protein) protein on a Calcitonin Receptor Like Receptor (CRLR). Also included in the present invention are methods and uses of such agents and assays for identifying such agents. The agents of the present disclosure may be used in the treatment of, for example, cancer, obesity and other disorders.Type: GrantFiled: August 3, 2010Date of Patent: November 25, 2014Assignee: Medella Therapeutics Ltd.Inventors: Timothy Michael Skerry, Gareth Owain Richards
-
Patent number: 8895007Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: GrantFiled: December 7, 2011Date of Patent: November 25, 2014Assignee: Affitech Research ASInventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovi{hacek over (c)} Kiprijanov
-
Patent number: 8894998Abstract: Targeted binding agents, such antibodies directed to the antigen ?V?6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen ?V?6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.Type: GrantFiled: February 6, 2013Date of Patent: November 25, 2014Assignee: MedImmune LimitedInventors: Julie Rinkenberger, Ian Foltz, Avril Alfred, Simon Thomas Barry, Vahe Bedian
-
Publication number: 20140341926Abstract: The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m2 repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least monthly to a patient in need of such treatment.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Applicant: Boehringer Ingelheim International GmbHInventors: Louis DENIS, Robert Michael LORENCE, Mehdi SHAHIDI, Flavio SOLCA
-
Patent number: 8889133Abstract: The present invention provides methods of preventing, treating or ameliorating diabetes by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists that block Dll4-Notch signal pathways. As observed in a mouse model of diabetes, Dll4 antagonists exhibit protective effects on pancreatic islets, lower blood glucose levels, and block the production of auto-antibodies, including those against insulin and glutamic acid decarboxylase 65 (GAD65), via the expansion of regulatory T cells (Tregs). Thus, the present invention further provides methods of lowering the levels of blood glucose, and/or reducing or blocking the production of auto-antibodies, by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists. Suitable Dll4 antagonists for the invention include antibodies or antibody fragments that specifically bind Dll4 and block Dll4-Notch interactions, the extracellular domain of Dll4, and the like.Type: GrantFiled: January 28, 2011Date of Patent: November 18, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventor: Dimitris Skokos
-
Patent number: 8883160Abstract: The prediction of protein function as well as the reconstruction of evolutionary genesis employing sequence comparison at large is still the most powerful tool in sequence analysis. Due to the exponential growth of the number of known protein sequences and the subsequent quadratic growth of the similarity matrix, the computation of the Similarity Matrix of Proteins (SIMAP) becomes a computational intensive task. The SIMAP database provides a comprehensive and up-to-date pre-calculation of the protein sequence similarity matrix, sequence-based features and sequence clusters. As of September 2009, SIMAP covers 48 million proteins and more than 23 million non-redundant sequences. Novel features of SIMAP include the expansion of the sequence space by including databases such as ENSEMBL as well as the integration of metagenomes based on their consistent processing and annotation.Type: GrantFiled: February 28, 2011Date of Patent: November 11, 2014Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Patent number: 8883164Abstract: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.Type: GrantFiled: December 23, 2011Date of Patent: November 11, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Sathibalan Ponniah, George E. Peoples, Catherine E. Storrer, Michael Flora
-
Patent number: 8883735Abstract: The present invention relates to LRP6 constructs that bind to LRP6 receptor. The LRP6 constructs comprise at least one LRP6 binding moiety and a half-life extender molecule such that the LRP6 construct inhibit the Wnt signaling pathway without potentiation of the Wnt signal. The LRP6 constructs also have an increased half-life to provide more time for the therapeutic benefit.Type: GrantFiled: November 2, 2012Date of Patent: November 11, 2014Assignee: Novartis AGInventors: David Jenkins, Ming Lei, Andreas Loew, Li Zhou
-
Patent number: 8883724Abstract: Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.Type: GrantFiled: November 4, 2009Date of Patent: November 11, 2014Assignee: Centro de Ingenieria Genética y BiotecnologiaInventors: Mónica Bequet Romero, Boris Ernesto Acevedo Castro, Jorge Victor Gavilondo Cowley, Luis Enrique Fernández Molina, Omar Lopez Ocejo, Ricardo de la Caridad Silva Rodriguez, Alexis Musachio Lasa, Ernesto Galban Rodriguez, Dania Marcia Vásquez Blomquist
-
Patent number: 8883153Abstract: One aspect of the present invention provides a method of treating or preventing angioedema in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R. One aspect of the present invention provides a method of treating or preventing vascular permeability in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R.Type: GrantFiled: March 29, 2010Date of Patent: November 11, 2014Assignee: The Research for The State University of New YorkInventor: Berhane Ghebrehiwet
-
Patent number: 8883151Abstract: The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.Type: GrantFiled: January 12, 2011Date of Patent: November 11, 2014Assignee: Kirin-Amgen, Inc.Inventors: Dingjiang Liu, Holly Zhuohong Huang, David Andrew Martin, Christopher Boyd Russell, David H. Salinger, Scott Walter Baumgartner, Christopher J. Endres
-
Publication number: 20140328904Abstract: The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.Type: ApplicationFiled: July 17, 2014Publication date: November 6, 2014Inventors: Carlos V. Paya Cuenca, Jan Henrik Ter Meulen